- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01225601
Prospective Evaluation of Adult Pulmonary Langerhans Cell Histiocytosis (LCHA1)
April 15, 2016 updated by: Assistance Publique - Hôpitaux de Paris
Epidemiology of Adult Adult Pulmonary Langerhans Cell Histiocytosis - A Multicenter Cohort Study
Study objectives:
- To estimate the incidence of pulmonary deterioration in adult pulmonary Langerhans cell histiocytosis
- To assess the impact of tobacco discontinuation
- Study Design Multicentric prospective cohort study
- Main endpoint: Pulmonary deterioration
- Sample size : 40 patients
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Study objectives To estimate the incidence of pulmonary deterioration in adult pulmonary Langerhans cell histiocytosis To assess the impact of tobacco discontinuation Study Design Multicentric prospective cohort study Main endpoint: Pulmonary deterioration Sample size : 40 patients
Study Type
Observational
Enrollment (Actual)
62
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Paris, France, 75010
- Hôpital Saint Louis
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Adult Pulmonary Langerhans cell histiocytosis
Description
Inclusion Criteria:
- Pulmonary Langerhans cell histiocytosis diagnosed within the past 48 months
Exclusion Criteria:
- Age < 18
- Deep pulmonary dysfunction (CPT< 60%, FEV1< 30%, DLCO< 30%, partial pressure of oxygen in arterial blood (PaO2)< 60mmHg)
- No informed consent or consent withdrawal
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Histocytosis
Adult with isolated pulmonary Langerhans cell histiocytosis (pulmonary LCH)
|
Tabacco discontinuation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pulmonary deterioration
Time Frame: 2 years
|
decrease in Forced expiratory volume in 1 second (FEV1), vital capacity (VC), or Diffusing capacity of the lung for carbon monoxide (DLCO) of at least 15% as compared to baseline values and/or progression of clinical symptoms (general symptoms) and/or occurrence of pneumothorax
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evolution of pulmonary volumes (FEV1)
Time Frame: 6 months
|
6 months
|
Evolution of pulmonary lesions in High Resolution Computed Tomography (HRCT)
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Abdellatif TAZI, MD PhD, Assistance Publique - Hôpitaux de Paris
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Tazi A, de Margerie C, Naccache JM, Fry S, Dominique S, Jouneau S, Lorillon G, Bugnet E, Chiron R, Wallaert B, Valeyre D, Chevret S. The natural history of adult pulmonary Langerhans cell histiocytosis: a prospective multicentre study. Orphanet J Rare Dis. 2015 Mar 14;10:30. doi: 10.1186/s13023-015-0249-2.
- Tazi A, de Margerie-Mellon C, Vercellino L, Naccache JM, Fry S, Dominique S, Jouneau S, Lorillon G, Bugnet E, Chiron R, Wallaert B, Valeyre D, Chevret S. Extrathoracic investigation in adult patients with isolated pulmonary langerhans cell histiocytosis. Orphanet J Rare Dis. 2016 Feb 2;11:11. doi: 10.1186/s13023-016-0387-1.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2006
Primary Completion (Actual)
May 1, 2009
Study Completion (Actual)
September 1, 2010
Study Registration Dates
First Submitted
October 12, 2010
First Submitted That Met QC Criteria
October 20, 2010
First Posted (Estimate)
October 21, 2010
Study Record Updates
Last Update Posted (Estimate)
April 18, 2016
Last Update Submitted That Met QC Criteria
April 15, 2016
Last Verified
March 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AOM 04141
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adult Pulmonary Langerhans Cell Histiocytosis
-
Assistance Publique - Hôpitaux de ParisCompletedPulmonary Langerhans Cell HistiocytosisFrance
-
University of CincinnatiNational Heart, Lung, and Blood Institute (NHLBI); Rare Diseases Clinical Research...CompletedPulmonary Langerhans Cell HistiocytosisUnited States
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingPulmonary Langerhans Cell HistiocytosisFrance
-
National Cancer Institute (NCI)RecruitingRecurrent Langerhans Cell Histiocytosis | Refractory Langerhans Cell HistiocytosisUnited States, Canada
-
Children's Oncology GroupNot yet recruitingRecurrent Langerhans Cell Histiocytosis | Refractory Langerhans Cell Histiocytosis
-
Case Comprehensive Cancer CenterSuspendedNon-Langerhans-Cell Histiocytosis | Langerhans Cell Histiocytosis (LCH) | Castleman's Disease (CD)United States
-
Masonic Cancer Center, University of MinnesotaTerminatedHistiocytosis, Langerhans-cellUnited States
-
Histiocyte SocietyCompletedChildhood Langerhans Cell HistiocytosisCanada, United Kingdom, United States, France, Germany, Austria, Ireland, Sweden, Italy, Argentina
-
Shanghai Changzheng HospitalThe First Affiliated Hospital of Nanchang University; Peking University People... and other collaboratorsRecruitingLangerhans Cell Histiocytosis of BoneChina
-
Assistance Publique - Hôpitaux de ParisActive, not recruitingLangerhans Cell Histiocytosis of LungFrance
Clinical Trials on Tabacco discontinuation
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, France; Pierre and...Unknown
-
University of ZurichCompletedSkin CancerSwitzerland
-
Hospices Civils de LyonInternational Agency for Research on CancerRecruitingLung or Head and Neck CancerFrance
-
University of CopenhagenDeerland Probiotics and EnzymesCompleted
-
University of Texas at AustinRecruitingPelvic Organ Prolapse | Stress Urinary Incontinence | Urinary Retention | Catheter Related ComplicationUnited States
-
West Virginia UniversityRecruiting
-
Josep Rodes-CabauRecruitingIschemic Stroke | Patent Foramen Ovale | Bleeding UlcerCanada
-
University of ChicagoRecruitingMultiple MyelomaUnited States
-
Leiden University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentActive, not recruiting
-
Baxter Healthcare CorporationCompleted